Frazier Healthcare Partners Announces $262M Life Sciences Fund
Menlo Park-based lifesciences investor Frazier Healthcare Partners announced a new, $262M life sciences fund this morning, Frazier Life Sciences VIII, L.P.. The fund closed with $262M in capital commitments, which it says it will invest exclusively in companies developing novel therapeutics. The company said the new fund brings its total under management to more than $2.4 billion. Details on the limited partners in the new fund were not announced. Frazier said the fund will focus on drug development ranging from early-stage, preclinical opportunities, to later-stage clinical development activities and specialty pharmaceutical companies.
posted on Thursday, October 29, 2015
Related companies:
Frazier Healthcare Ventures
Related stories:
> SutroVax Finds $64M For Pneumococcal Vaccines
> Technology Partners Raises $300M For Cleantech, Life Sciences
> CardioKinetix Gets $44M
> FlowCardia Garners $30M
> Gilead Sciences Buys Calistoga Pharmaceuticals
silicontap.com Home